In a 20-question test of neurologists (6 with MS specialty) and AI platforms, the bots did better than all but the ...

A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...

The FDA expanded the indication of eculizumab (Soliris) to include pediatric patients ages 6 and older with generalized ...

The company was previously housed at the BioScience Center, an Uptown incubator focused on bioscience and life-science ...

Disparities exist in access to rehabilitation following community discharge for traumatic brain injury (TBI) in olde ...

For patients with severe oral commissure droop from facial nerve damage undergoing surgery, botulinum toxin type A ( ...

UK: A recent systematic review and meta-analysis published in Neurosurgical Review shed light on the significant role of preoperative oedema in predicting seizure risk in patients with ...

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data from the study PFO-ACCESS: Augmenting Communications for Medical Care or Closure ...

About 40% of patients in primary care have pain or illness that cannot be explained by diagnostic tests. It is commonly assumed that the symptoms are “all in their heads,” and that little or nothing ...

New research suggests that having a higher VO2 max is linked with a lower risk of cognitive decline. Here's why that is, and how you can improve your numbers.

Sangamo posted a Q4 loss of $0.11 per share, $0.01 worse than the $0.10 loss analysts had forecast. Revenue for the quarter came in at $7.55 million, missing the consensus estimate of $10.32 million.

If asked to name someone famous, fictional or real who is 'on the spectrum', most people give the same sorts of replies.